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Dry Needling Alters Trigger Points in the Upper Trapezius Muscle
and Reduces Pain in Subjects With Chronic Myofascial Pain
Lynn H. Gerber, MD, Jay Shah, MD, William Rosenberger, PhD,
Kathryn Armstrong, DPT, Diego Turo, PhD, Paul Otto, BS, Juliana Heimur, BS,
Nikki Thaker, BS, Siddhartha Sikdar, PhDAbstractObjective: To determine whether dry needling of an active myofascial trigger point (MTrP) reduces pain and alters the status of
the trigger point to either a nonespontaneously tender nodule or its resolution.
Design: A prospective, nonrandomized, controlled, interventional clinical study.
Setting: University campus.
Participants: A total of 56 subjects with neck or shoulder girdle pain of more than 3 months duration and active MTrPs were
recruited from a campus-wide volunteer sample. Of these, 52 completed the study (23 male and 33 female). Their mean age was
35.8 years.
Interventions: Three weekly dry needling treatments of a single active MTrP.
Main Outcome Measures: Primary Outcomes: Baseline and posttreatment evaluations of pain using a verbal analogue scale, the
Brief Pain Inventory, and the status of the MTrP as determined by digital palpation. Trigger points were rated as active
(spontaneously painful), latent (requiring palpation to reproduce the characteristic pain), or resolved (no palpable nodule).
Secondary Outcomes: Profile of Mood States, Oswestry Disability Index, and Short Form 36 scores, and cervical range of motion.
Results: Primary outcomes: A total of 41 subjects had a change in trigger point status from active to latent or resolved, and 11
subjects had no change (P < .001). Reduction in all pain scores was significant (P < .001). Secondary outcomes: Significant
improvement in posttreatment cervical rotational asymmetry in subjects as follows: unilateral/bilateral MTrPs (P ¼ .001 and
P ¼ 21, respectively); in pain pressure threshold in subjects with unilateral/bilateral MTrPs, (P ¼ .006 and P ¼ .012, respectively);
improvement in the SF-36 mental health and physical functioning subscale scores (P ¼ .019 and P ¼ .03), respectively; and a
decrease in the Oswestry Disability Index score (P ¼ .003).
Conclusions: Dry needling reduces pain and changes MTrP status. Change in trigger point status is associated with a statistically
and clinically significant reduction in pain. Reduction of pain is associated with improved mood, function, and level of disability.Introduction
Myofascial pain syndrome (MPS) is a common and
significant clinical problem, accounting for 15% of gen-
eral medical visits [1]. MPS negatively affects function
and participation in life activities [2,3].
MPS has generated controversy in part because
there has been disagreement about diagnostic
criteria. The syndrome has had many names, in-
cluding fibrositis, myofasciitis, and myogelosis [4,5],
reflecting a lack of agreement about etiology, path-
ophysiology, and the primary tissue involved. MPS has
been confused with other pain syndromes such as1934-1482ª 2015 by the American Academy of Physical Medicine and Reh
http://dx.doi.org/10.1016/j.pmrj.2015.01.020fibromyalgia and neuropathic pain, and although
confusion remains, there is general acceptance of the
term “myofascial paiin syndrome” and its diagnostic
components [6-8].
There is active debate about whether the myofascial
trigger point (MTrP) is a necessary condition for the
diagnosis of MPS, and whether it should be the target for
pain relief. This article explored this relationship in part
because there seems to be agreement that the MTrP is
an objective finding associated with MPS that is reliably
identified and useful in assessing pain [9-12].
In this study, we used Travell and Simons’ definition
of MPS, namely a regional pain syndrome in which thereabilitation
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712 Dry Needling for Myofascial Painis a palpable, discrete nodule within a taut band of
skeletal muscle that is spontaneously painful [9,10].
This is referred to as an active trigger point (a-MTrP),
defined as a spontaneously painful nodule. A latent
myofascial trigger point (l-MTrP) is a trigger point that is
not spontaneously painful and that requires palpation or
motion/activity to induce pain.
Dry needling is a nonpharmacological treatment for
MPS that is commonly used for reducing pain associated
with a-MTrPs [13,14]. It is frequently performed by a
clinician using a 32-gauge acupuncture needle inserted
into the palpably painful nodule using a superficial (10-
20 mm) or deep (25-40 mm) needling technique. Elici-
tation of 1 or more local twitch responses is a goal of dry
needling and often benefits individuals with pain sec-
ondary to MTrPs [3].
The effectiveness of dry needling has been difficult to
demonstrate due to a lack of objective measures of
pain. Currently, assessment of patients with MPS relies
upon patient self-reports of pain. Patient-reported
outcomes (PROs) are reliable measures, but their
sensitivity to change, the variety of ways of expressing
pain by individual patients, correlations with physical
findings, and other objective measures have made
validation difficult.
Our research team used the status of the MTrP as the
treatment target and an outcome measure to assess the
changes that resulted from treatment and to determine
whether change in its status correlated with change in
posttreatment level of pain.
This article presents the results of a prospective,
interventional clinical study designed to assess whether
dry needling of an a-MTrP alters patient-reported pain
and contemporaneously alters the status of the trigger
point. We selected a technique that is widely used in
clinical practice and that has been shown to be effec-
tive in reducing MPS, but effect of which on the MTrP is
not known [3,13,14]. We also measured the impact of
dry needling on self-reports of mood and function.
To our knowledge, this is the first study to investigate
the association between dry needling and its effect on
pain reduction and MTrP status.
Methods
The study was approved by the Chesapeake Institu-
tional Review Board. Subjects were recruited by posting
flyers around a university community. No remuneration
was offered to participants. All provided consent.
Study entry required that participants were adult (aged
18-65 years) and had experienced pain without provoca-
tion for at least 3 months in the neck/shoulder girdle re-
gion and a palpable MTrP in 1 or both of the specific
locationsof theupper trapezius.The spontaneouspainhad
to be in the area of the prescribed MTrP locations, and its
palpationhad toexacerbatepain.Radiation tohead,neck,
or face on palpation was acceptable but was not requiredfor inclusion. All evaluations and treatments were per-
formed by 2 experienced clinicians, each with more than
20 years of treatment experience. Patients selected
which day of the week was preferable for treatment and
follow-up, andwere assigned to the physicianwho treated
on a specific day of the week. That is, physician 1 treated
on Fridays and physician 2 on Thursdays. Occasionally,
patients were seen on the alternative day if scheduling
required a change.
Interobserver reliability for the 2 treating physicians
was tested using 14 treatment-naive volunteers with
and without pain. Each provided informed consent for
evaluation. Two sites were examined independently by
each of the two examiners and scored as active, latent,
or nonpainful nodule/normal. Interrater reliability was
assessed using a k statistic. The k statistic for site 2 is
0.74 (P ¼ .003) and for site 3 is 0.87 (P < .001).
Entry exclusions included the following: chronic fa-
tigue syndrome, fibromyalgia, chronic Lyme disease,
cervical radiculopathy, head/neck/shoulder girdle sur-
geries, new medication or change within 6 weeks, and
current use of acupuncture.
All study subjects received 3 successive dry needling
sessions weekly. Posttreatment evaluations were per-
formed at 3 weeks. Treatment technique was stan-
dardized as follows: 4 predetermined examination areas
were palpated and point(s) were identified [2]. They
were 2 cm medial to the acromioclavicular joint on the
left and right sides and at 2 additional sites in the upper
trapezius as it turns cephalad lateral to the spinous
process of C7. Trigger points reported to be spontane-
ously painful were considered to be a-MTrP; those not
spontaneously painful but painful upon palpation were
designated as l-MTrPs. Only 1 a-MTrP was selected for
treatment. If there was more than 1 a-MTrP, we
selected the most symptomatic site for dry needling.
Hence, there may have been untreated a-MTrPs.
Some subjects had a-MTrPs on only 1 side, which we
defined as “unilateral.” Some subjects had at least 1 a-
MTrP on each side, which we defined as “bilateral.” We
defined “responders” as patients whose status changed
from a-MTrP to l-MTrP, or a-MTrP to an asymptomatic
palpable nodule or no nodule palpable. “Non-
responders” were those whose a-MTrP remained active
(spontaneously painful). This status was determined by
a treating physician (not always the one who performed
the dry needling treatment) who palpated and assessed
whether the findings were consistent with a-MTrP, l-
MTrP, nonpainful nodules, or no palpable nodule.
The selected a-MTrP was prepared by wiping the area
with an alcohol pad, and a 32-gauge needle with its
plastic guide tube in place was placed over the a-MTrP
(Figure 1). A tapping motion was used to advance the
needle. Occasionally, needle movement was performed
around the nodule following a 4-points-of-compass
technique with rotation along its long axis in an effort to
elicit a small muscle twitch. This was achieved in
Figure 1. Demonstration of needle insertion into myofascial trigger
point.
Figure 2. Algometer used for measuring pain pressure threshold (Tech
Medical, Salt Lake City, UT).
713L.H. Gerber et al. / PM R 7 (2015) 711-720approximately 70% of subjects on the first, 66% on the
second, and 50% on the third treatment. Change in
verbal analogue scale (VAS) score was not statistically
correlated with eliciting the twitch response.
All evaluations were performed at baseline and after
the third treatment at 3 weeks. Primary outcomes were
measures of pain reduction and change in trigger point
status from a-MTrP to either l-MTrP or no palpable
nodule. A VAS was used for pain assessment. It was
scored from 0 to 10 (0 ¼ no pain, 10 ¼ unbearable pain).
The question was asked as follows: “Are you having pain
now? Please rate it on a scale of 0-10. Do you have pain
on the right side of your neck? Please rate this 0-10. Do
you have pain on the left side of your neck? Please rate
this 0-10.” Palpation was performed on 4 standard sites.
Nodules were either active (spontaneously painful),
latent (required overpressure to elicit pain), or not
palpable (and no pain associated with palpation).
Secondary outcomes included range of motion (ROM)
which was determined in 3 planes of movement
(flexion/extension, side bending, and rotation) using
the Deluxe Cervical Range of Motion Instrument (CROM),
model 12-1156 (Fabrication Enterprises, White Plains,
NY). A ratio of measures of ROM over the normal range
was determined for the left and right sides. The asym-
metry was evaluated at baseline and at the end of
treatment (3 weeks). Two additional measures of pain
included a measure of pain pressure threshold (PPT) and
the Brief Pain Inventory (BPI) [15]. PPT was obtained at
4 sites, following a standard procedure for assessing
relative comparisons among the anatomical sites using a
pressure algometer (Commander Algometer, Tech Med-
ical, Salt Lake City, UT; http://www.jtechmedical.com/
Commander/commander-algometer) (Figure 2). Sub-
jects were instructed to identify the moment at which
symptoms underwent a qualitative shift from pressure
to pain during algometer compression. The reading at
that time was determined to be the PPT score. A highscore, namely, that which requires more pressure to be
applied to produce pain, was associated with improved
pain symptoms.
Additional measures included the Oswestry Disability
Index, a measure of disability secondary to the spine
and adjacent musculoskeletal system. Subjects were
instructed to reply with reference to the neck and upper
thoracic area in terms of limitations [16]. The MOS 36-
Item Short-Form Health Survey (SF-36), a health status
questionnaire [17] was used, as well as a short version of
the Profile of Mood States (POMS) [18], a symptom
checklist of mood that included such items as anxiety
and depressive symptoms. Subjects with high scores on
the Oswestry Disability Index, POMS, and VAS were
considered to be more symptomatic or more disabled. A
high score on the SF-36 was considered to indicate
better health status.
Sample size was determined to be 90 subjects, with the
assumption that 5% of patients would spontaneously
improve their MTrP status without dry needling. We
wished to detect an increase of 10% for responders post-
treatment. We conducted a conditional power analysis
after 56 patients were accrued and determined the study
to be substantially overpowered, and our hypothesized
percentage of responders was underestimated [19].
StatXact [20] was used to conduct an exact binomial
test that the percentage of responders exceeded 5% at
the 0.05 (2-sided) a level. Paired t-tests compared pain
and variables of interest before and after treatment.
These variables included both objective and self-
reported outcomes. Analysis of covariance was used to
detect changes in outcome measures for responders
versus nonresponders.
Changes from baseline in VAS, BPI, and PPT scores
were analyzed, and were adjusted for baseline value,
714 Dry Needling for Myofascial Painage, gender, group (unilateral/bilateral), and exercise
status, based on response to treatment, using regression
analysis. For all models, studentized residual plots were
inspected. For VAS scores and BPI scores, the residuals
appeared homoscedastic with no outliers. For PPT scores,
1 subject was considered as an outlier. A Q-Q plot of
residuals exhibited no indication of nonnormality.
Each model was adjusted for gender, age, and exer-
cise status, and none of these characteristics was
significant in any of the models. Regression diagnostics
were graphically depicted, including checks for outliers
and heteroscedasticity, and Q-Q plots to verify the
normal error assumption. There were no outliers, and no
transformations were deemed necessary. All regression
analyses were conducted using SAS software, version 9.3
(SAS Institute, Cary, NC).
Results
In all, 52 subjects were included in the study. A total
of 56 were originally eligible and underwent study
baseline procedures. Two subjects did not complete 3
weekly dry needling sessions and dropped out for un-
known reasons. One subject started new treatments
after the first study treatment, and 1 subject did not
have complete follow-up data for analysis. Table 1
presents the distribution of the descriptive variables
and a summary of treatments that subjects had selected
for their pain before study entry.
Table 2 presents the frequencies for the primary
outcome in bilateral and unilateral groups, respectively.
There were 41 responders and 11 nonrespondersTable 1
Characteristics of study subjects
Characteristic
Active Myofascial Trigger Points
n %
Gender
Male 23 41.1
Female 33 58.9
Age, y
Mean (range) 35.8 (20-62)
Pain distribution
Bilateral 42 75
Unilateral (right/left) 9/5 16.1/8.9
Pain duration, y
<3 21 37.5
>3 35 62.5
Use of medication
Analgesic 37 66
Mood 11 19.6
Sleep 1 1.8
Opioid/Narcotic 0 0
Supplements/vitamins 30 53.6
Use of nonpharmacological treatment
Exercise 43 76.6
Physical Modalities (heat, cold,
electrical stimulation)
32 57
Massage 17 30
Chiropractic 8 14(P < .001). A conditional power analysis was conducted.
Under the current trend of the data, under the hypo-
thetical trend of the data, and under the null hypoth-
esis, the conditional power was 1, meaning that there
was no positive probability of a nonsignificant result
using the full sample size.
Table 3 presents baseline and follow-up characteristics
for physical findings, pain, and self-reports. We measured
a significant improvement in rotational asymmetry in
both the unilateral and bilateral groups (P ¼ .001 and
P ¼ .021, respectively). ROM extension and flexion had
not improved. There was a significant change in side-
bending ROM in the unilateral group only (P ¼ .001) and
a significant improvement in PPT at the treated site in
both groups (P ¼ .006 and P ¼ .012, respectively). The
baseline and follow-up characteristics for pain measure-
ments and self-reports showed a significant reduction in
BPI scores (P < .001). There was a significant reduction in
VAS on the treated side in both the unilateral and bilat-
eral groups (P < .001), and on the untreated side only in
the bilateral group (P < .001). There was a significant
increase in the SF-36 pain subscale score (P ¼ .002) and a
decrease in the POMS tension and mood scores (P ¼ .012
and P ¼ .013, respectively). These represented improve-
ments. There was significant improvement in the scores of
the SF-36 mental health and physical functioning sub-
scales (P ¼ .019 and P ¼ .03, respectively) and the
Oswestry Disability Index scores (P¼ .003). The regression
model was significant for VAS scores (model F ¼ 32.37,
P < .001, R2 ¼ 0.81, n ¼ 52). Baseline values for VAS were
also significant (P < .001). Other adjustment variables
were not significant. For BPI scores, the regression model
was marginally significant (model F ¼ 2.36, P ¼ .047,
R2 ¼ 0.25, n ¼ 49). For PPT, the regression model was not
significant (model F ¼ 2.13, P ¼ .069, R2 ¼ 0.22, n ¼ 51).
Only baseline PPT was significant in the model.
Table 4 presents the least-squares means (standard
errors) for change from baseline in VAS, BPI, and PPT
among responders and nonresponders from the adjusted
regression models. The mean change from baseline in
VAS score was 2.87  0.16 for responders and 1.00
 0.30 for nonresponders. The means were significantly
different (P < .001). The mean change from baseline in
BPI score was 1.32  0.22 for responders and 0.04
 0.38 for nonresponders. The means were significantly
different (P ¼ .002). The mean change from baseline in
PPT was not statistically significantly different in
responders and nonresponders.Table 2
Primary outcome for treated subjects with bilateral and unilateral
active trigger points
Bilateral Active Trigger Points Unilateral Active Trigger Points
Baseline Follow-up Count Baseline Follow-up Count
Active Active 7 Active Active 4
Active Latent 12 Active Latent 14
Active Normal 6 Active Normal 9
Table 3
Baseline and follow-up characteristics: Physical findings, pain and self-reported outcomes (mean  SD)
Characteristic n Baseline Follow-up P value
Physical finding
Cervical ROM extension () 51 73.8  12.8 74.3  12.0 .741
Cervical ROM flexion () 51 55.2  11.0 57.1  8.3 .192
Rotation asymmetry unilateral () 27 8.1  6.3 3.1  5.4 .001
Rotation asymmetry bilateral () 24 5.4  4.4 2.4  3.2 .021
Side bending unilateral () 27 5.6  3.8 2.7  2.9 .001
Side bending bilateral () 24 5.5  6.4 3.1  3.2 .109
PPT treated site unilateral (lb) 27 7.6  3.3 9.4  3.7 .006
PPT treated site bilateral (lb) 24 6.7  3.0 8.4  3.1 .012
Pain (scores)
BPI 49 3.4  1.6 2.3  1.9 <.001
VAS treated side unilateral 27 3.5  2.4 0.9  1.3 <.001
VAS treated side bilateral 25 3.0  1.4 0.9  1.2 <.001
VAS untreated side unilateral 27 1.0  1.9 0.4  1.1 .203
VAS untreated side bilateral 25 2.6  1.2 0.9  1.2 <.001
SF-36 pain 50 62.5  18.4 69.3  16.5 .002
Self-reported outcomes
POMS confusion 49 0.28  0.39 0.23  0.35 .418
POMS depression 49 0.11  0.23 0.07  0.18 .151
POMS fatigue 49 0.77  0.81 0.54  0.69 .056
POMS tension 49 0.47  0.50 0.28  0.33 .012
POMS mood 49 0.29  1.91 0.38  1.79 .013
POMS vigor 49 1.49  0.94 1.58  0.93 .261
POMS anger 49 0.15  0.35 0.08  0.27 .12
SF-36 general health 50 76.9  19.1 76.8  18.6 .913
SF-36 mental health 50 75.9  11.8 79.1  11.4 .017
SF-36 physical functioning 50 88.5  14.3 91.4  11.3 .03
SF-36 emotional 50 83.4  21.5 88.8  16.3 .051
SF-36 physical role 50 85.1  17.0 86.9  16.7 .471
SF-36 social functioning 50 87.8  16.9 89.7  15.9 .253
SF-36 vitality 50 58.7  17.0 60.7  16.9 .258
Oswestry Disability Index score 50 10.8  6.0 8.5  7.1 .004
BPI ¼ Brief Pain Inventory; PPT ¼ pressure pain threshold; POMS ¼ Profile of Mood States; ROM ¼ range of motion; SF-36 ¼ MOS 36-Item Short-Form
Health Survey; VAS ¼ verbal analogue scale.
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Much has been written about MTrPs and their possible
relationship to MPS [21-24]. The contribution of the
MTrP in the pathogenesis of MPS is an area of active
investigation and has raised important questions about
muscle and fascia in inciting and perpetuating soft-
tissue pain [25-27]. Debate continues as to whether
the MTrP is necessary for MPS diagnosis and whether it
needs to be the target of treatment.
The pathogenesis of the MTrP is elusive, and current
explanations about its relationship to MPS remainTable 4
Change from baseline on VAS, BPI, and PPT
VAS score BPI score PPT (lb)
Responders 2.87  0.16 1.32  0.22 2.12  0.50
Nonresponders 1.00  0.30 0.04  0.38 0.85  0.96
Data are least-squares means  standard errors of change from
baseline of VAS, BPI, and PPT, and are adjusted for baseline, site,
gender, age, and exercise status.
VAS ¼ verbal analogue scale; BPI ¼ Brief Pain Inventory; PPT ¼ pain
pressure threshold.incomplete. Trauma, muscle overload, and muscle over-
use have been cited as etiologic agents, with trauma
being 1 of the leading contenders [24,25]. Tissue injuries
result in the release of noxious substances that bind to,
sensitize, and/or activate nociceptors. This leads to the
transmission of signals that indicate tissue damage and
inflammation, and may set up persistent pain states [26].
The relative contributions of the central and peripheral
nervous systems in generating and perpetuating pain are
not yet fully understood, although there is preliminary
evidence for pain dysregulation in MPS [28-30]. Disrupted
descending inhibition in individuals with chronic muscu-
loskeletal pain may lead to a muscle pain complaint,
irrespective of peripheral tissue damage [30].
To explore relationships between MTrPs and MPS, we
reasoned that if treatment directed at the MTrP was
shown to improve myofascial pain [3,14,31-34], we
could measure changes in pain and MTrP status at the
same time. We elected to use a single MTrP in a defined
anatomical area and to use experienced “calibrated”
examiners to study it carefully. The examiners partici-
pated in a test of interrater reliability that demon-
strated no statistically significant differences between
716 Dry Needling for Myofascial Paintheir clinical assessments. This approach would provide
an opportunity to assess pain related to the MTrP and
would allow us to determine the relationship, if any,
between pain reduction and MTrP status change. We
used objective measures of the MTrP (palpation and
size) [35], and correlated these with patient self-reports
of pain, mood, health status, and disability. One review
article addressing the reliability of palpation suggests
that it varies widely [34]. However, none of these
9 studies used examiners who had demonstrated inter-
rater reliability and performed evaluation and treat-
ment on a single muscle.
Our major findings were that pain reduction, as
measured using all 3 of the pain assessments, is signifi-
cantly correlated with change in the MTrP status as
determined by MTrP palpation from active to latent or
normal (no palpable nodule) after dry needling. We
noted that there was a clinically significant improve-
ment in pain scores (a drop of 2) on the VAS [36].
Treatment was correlated with a significant, clinically
relevant reduction in pain compared with baseline
values, as well as improvements in mood and function.
Needling was also positively correlated with a significant
increase in cervical ROM attributable to the upper
trapezius (i.e., side bending and rotation). There was a
significant decrease in asymmetry between the left and
right sides after treatment.
We are aware of some concerns about the reliability
of pain measures and therefore used 3 instruments. One
of these, the PPT, is an instrumented measure. All
showed significant reduction after treatment.
The mean baseline measurement of pain for subjects
with unilateral MTrP was VAS 3.5 (SD 2.4), which is
considered moderate pain [37]. The group with bilateral
MTrPs had VAS score of 3.0 (1.4), indicating mild pain.
Some clinicians may not wish to treat MTrP and myofas-
cial pain if the level is mild. The decision to treat often
depends upon several factors, including frequency and
persistence, intrusion into daily activities, and peak pain
levels. The measure at baseline was determined at a
moment in time, and the entry criterion was reportable
pain; the clinical severity did not determine whether the
research subject was to receive dry needling. After
criteria were met, our primary outcome was a change in
pain score, and the change was significant.
Appropriate measurement is critical to ensure the
validity and reliability of this clinical study. Pain eval-
uations are not objective assessments, and consensus
about which pain assessment tools are best to use for
this study group has not been reached. This study used
standard, systematically applied, and frequently used
evaluations to assess patients with MPS. We used the BPI
and algometry to assess the level and nature of pain.
Although both the BPI and VAS measured pain intensity
at the time of administration, the BPI also measured the
impact of pain on daily functions, pain relief, pain
quality, and the patient’s perception of the cause of thepain. The statistical analysis showed that VAS and BPI
adjusted means scores were significantly different after
treatment, and that PPT scores were not. In the regres-
sion model, VAS was significant, BPI was marginally sig-
nificant, and PPT was not. We support the use of the VAS
for assessment of treatment of MPS. PPT may be useful
and has been shown to be reliable in evaluating MPS, but
it lacks sensitivity [38]. In this study, we have defined a
positive response to treatment as a statistically signifi-
cant decrease in pain from baseline and improvement in
MTrP status. The change was also clinically significant,
that is a decrease in 2 points on the VAS.
We recommend a careful, systematic, and compre-
hensive approach to the evaluation of patients with
MPS. This approach should include objective measures
of cervical spine ROM, trigger point palpation and self-
reports of pain, fatigue, mood, disability and health
status, which have been shown to be sensitive to change
and to provide important information about the impact
of MPS on issues of importance to patients.
One review examined the level of evidence for dry
needling in MPS [14]. The authors identified the data as
level 1a because the reports were randomized, placebo-
controlled trials. The outcomes were self-reports, did
not include objective measures, and did not link
response to trigger point status.
To the best of our knowledge, this is the first report to
demonstrate that there is a significant, contemporaneous
change in the level of both pain and the status of the
MTrP after dry needling. Dry needling is likely to provide
pain reduction and resolution of the a-MTrP. We report
that dry needling has a significant effect in reducing pain
as measured by VAS, BPI, and PPT; and in decreasing
disability as measured by the Oswestry Disability Index in
individuals with MPS and a-MTrPs. A randomized,
placebo-controlled, blinded trial is the gold standard and
is required to definitively demonstrate effectiveness. Our
group is planning to conduct such a trial.
There are some limitations to this study. MPS has long
been considered a local or regional pain syndrome,
implying that the inciting factors for pain are local
rather than resulting from central sensitization [39,40].
This study did not address this question. The results of
this study do not answer questions about pathogenesis,
etiology, and relative contributions of various regulatory
mechanisms for developing or resolving MPS or MTrPs.
However, the data advance our understanding of this
complex syndrome by linking improvement in symptoms
with objective measures of MTrP and establish a rela-
tionship between MTrP and MPS.
Subjects for this study were recruited on a university
campus, and possibly represent an atypical cross-section
of people with MPS. Nonetheless, computer-based activ-
ity is used by most of our subjects, and has been reported
to be a significant risk factor for developing MPS [41].
Finally, this study was not a randomized, placebo-
controlled, blinded clinical trial; hence it cannot prove
717L.H. Gerber et al. / PM R 7 (2015) 711-720effectiveness. The treating clinicians also evaluated the
subjects, creating potential bias despite their being
experienced and standardizing their technique [42,43].
The 2 treating physicians evaluated and treated the
subjects based on scheduling convenience, and any bias
introduced as a result cannot be ruled out. Not all
subjects responded with a twitch to the dry needling.
Some investigators believe that this is an important part
of the therapeutic effect [3,42]. The elicitation of the
twitch response did not distinguish the responders from
the nonresponders in this study.
This study was also had advantages. The study was a
carefully conducted, systematic prospective study using
valid instruments designed to measure soft tissue pain
and disability to which objective measures were also
applied. This permitted us to develop a properly sized
and designed clinical effectiveness trial for dry needling
using self-reported outcomes and objective measures.Conclusion
A 3-week course of dry needling had a significant
effect on pain reduction in MPS. Pain reduction was
significantly related to change in trigger point status
from active (spontaneously painful) to latent or reso-
lution. Importantly, pain reduction was significantly
correlated with improvement in cervical spine side
bending and rotation, in patient self-reports of
improved physical and emotional well-being and mood;
and reduction in disability.References
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